246 related articles for article (PubMed ID: 25351958)
21. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
22. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
23. PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway.
MacKenzie KF; Clark K; Naqvi S; McGuire VA; Nöehren G; Kristariyanto Y; van den Bosch M; Mudaliar M; McCarthy PC; Pattison MJ; Pedrioli PG; Barton GJ; Toth R; Prescott A; Arthur JS
J Immunol; 2013 Jan; 190(2):565-77. PubMed ID: 23241891
[TBL] [Abstract][Full Text] [Related]
24. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI
Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004
[TBL] [Abstract][Full Text] [Related]
25. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
[TBL] [Abstract][Full Text] [Related]
26. Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling.
Ha YNE; Dai Y; Wufuer D; Pidayi M; Anasihan G; Chen L
Neoplasma; 2020 Jan; 67(1):54-60. PubMed ID: 31777258
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
Piera-Velazquez S; Jimenez SA
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):36-44. PubMed ID: 30277861
[TBL] [Abstract][Full Text] [Related]
28. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1
Gleixner KV; Sadovnik I; Schneeweiss M; Eisenwort G; Byrgazov K; Stefanzl G; Berger D; Herrmann H; Hadzijusufovic E; Lion T; Valent P
Leuk Res; 2019 Mar; 78():36-44. PubMed ID: 30711891
[TBL] [Abstract][Full Text] [Related]
29. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Skoglund K; Boiso Moreno S; Jönsson JI; Vikingsson S; Carlsson B; Gréen H
Pharmacogenet Genomics; 2014 Jan; 24(1):52-61. PubMed ID: 24322003
[TBL] [Abstract][Full Text] [Related]
30. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
31. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
32. Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer.
Gordian E; Li J; Pevzner Y; Mediavilla-Varela M; Luddy K; Ohaegbulam K; Daniel KG; Haura EB; Muñoz-Antonia T
PLoS One; 2014; 9(12):e114131. PubMed ID: 25501935
[TBL] [Abstract][Full Text] [Related]
33. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
34. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
Muresan B; Mamolo C; Cappelleri JC; Leip E; Viqueira A; Heeg B
Curr Med Res Opin; 2021 May; 37(5):801-809. PubMed ID: 33733983
[TBL] [Abstract][Full Text] [Related]
35. Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth.
Tauer JT; Hofbauer LC; Jung R; Erben RG; Suttorp M
Med Sci Monit Basic Res; 2013 Nov; 19():274-8. PubMed ID: 24185529
[TBL] [Abstract][Full Text] [Related]
36. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors.
Beetham H; Griffith BGC; Murina O; Loftus AEP; Parry DA; Temps C; Culley J; Muir M; Unciti-Broceta A; Sims AH; Byron A; Brunton VG
Cancer Res; 2022 Feb; 82(4):632-647. PubMed ID: 34921014
[TBL] [Abstract][Full Text] [Related]
37. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
[TBL] [Abstract][Full Text] [Related]
38. Dectin-1 regulates IL-10 production via a MSK1/2 and CREB dependent pathway and promotes the induction of regulatory macrophage markers.
Elcombe SE; Naqvi S; Van Den Bosch MW; MacKenzie KF; Cianfanelli F; Brown GD; Arthur JS
PLoS One; 2013; 8(3):e60086. PubMed ID: 23533666
[TBL] [Abstract][Full Text] [Related]
39. Molecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and Coevolution.
Tse A; Verkhivker GM
PLoS One; 2015; 10(6):e0130203. PubMed ID: 26075886
[TBL] [Abstract][Full Text] [Related]
40. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
